Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are studying how the liver condition called hepatic impairment affects the way two drugs, AZD9550 and AZD6234, behave in the body. This Phase I, open-label study focuses on safety, tolerability, and how the body processes these drugs in people with severe or moderate liver impairment compared to healthy individuals with normal liver function. The study classifies participants based on Child-Pugh scores to assess the severity of liver impairment. Participants receive a single subcutaneous under the skin dose of AZD9550 first, followed by AZD6234 after a washout period to reduce any drug interaction effects. The study includes groups with severe hepatic impairment Child-Pugh Class C, moderate hepatic impairment Class B, and matched healthy controls. The drugs are administered separately during two study periods to evaluate their individual effects. During the study, participants undergo screening and receive the study drugs with monitoring for safety, immune response, and drug levels over 56 days. Assessments include blood tests, physical exams, and vital sign monitoring to track pharmacokinetics and any adverse effects. Researchers measure drug exposure AUCinf, AUClast, Cmax and secondary parameters like half-life and clearance. The study lasts until the primary completion date with ongoing safety and tolerability evaluation.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the pharmacokinetics, safety, and tolerability of capivasertib in adults with moderate hepatic impairment compared to those with normal liver function. This Phase I, single-dose, non-randomized, open-label study aims to understand how the drug behaves in the body under these conditions and to monitor its safety. The study includes participants aged 18 to 80 years and is sponsored by AstraZeneca. Participants will be divided into two groups those with moderate hepatic impairment and those with normal liver function. Each participant will receive a single oral dose of capivasertib while residing at the study site from the day before dosing through four days after. Participants with hepatic impairment will have an additional liver function stability assessment during screening. After dosing, participants will return for a follow-up visit 9 to 11 days later. During the study, participants will undergo blood sampling to measure capivasertib concentrations and various pharmacokinetic parameters such as maximum plasma concentration and area under the curve from day 1 to day 4. Researchers will also monitor adverse events up to day 11 to assess safety. The total participation lasts from screening through follow-up visits, with close monitoring during residence at the study site.
Actively Recruiting
Researchers are evaluating an investigational drug called ALN-HSD for adults with Metabolic Dysfunction-Associated SteatoHepatitis MASH, a liver condition marked by fat buildup, inflammation, and scarring that can lead to cirrhosis and liver failure. This Phase 2 study aims to understand how ALN-HSD affects liver scarring and inflammation in participants who have genetic risk factors for MASH. Participants are randomly assigned in a 11 ratio to receive either ALN-HSD or a placebo. The study is double-blind and quadruple-masked, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment is administered according to the study protocol over a period of 52 weeks, with follow-up monitoring extending to 84 weeks to assess safety. During the study, participants will undergo various assessments including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and genetic evaluations. Researchers will track changes in liver fibrosis and inflammation as well as the presence of drug metabolites in blood samples. Safety is monitored throughout the study and beyond the treatment period. The total duration of participation is up to 84 weeks.
Actively Recruiting
The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.
Actively Recruiting
Researchers are evaluating the pharmacokinetic and safety profiles of a single dose of efimosfermin alfa in adults with different levels of liver impairment caused by steatotic liver disease. The study focuses on participants who have hepatic impairment classified by the Child-Pugh score, with or without significant alcohol consumption. This is a phase 1, open-label study assessing efimosfermin alfa in adults aged 18 to 70 with metabolic dysfunction-associated steatohepatitis MASH. All participants will receive a single subcutaneous dose of efimosfermin alfa. The study includes three groups based on the degree of hepatic impairment and alcohol use moderate impairment with low alcohol consumption, moderate impairment with higher alcohol consumption, and severe impairment regardless of alcohol use. The study uses a sequential design to evaluate these groups. Participants will be monitored up to 90 days after dosing. Researchers will measure drug concentration in blood over time and monitor for adverse events, changes in lab results, vital signs, and ECG readings. The main outcomes include drug exposure levels and safety assessments to understand how hepatic impairment affects efimosfermin alfa pharmacokinetics. Participants will have regular assessments during this period to track these outcomes.
Actively Recruiting
Researchers are evaluating the safety, tolerability, preliminary effectiveness, and how the body processes efimosfermin in adults with metabolic dysfunction-associated steatohepatitis MASH and compensated cirrhosis showing stage F4 fibrosis. This study focuses on people diagnosed by liver biopsy with advanced but stable liver disease caused by metabolic problems. It aims to understand the impact of efimosfermin on this condition. Participants will be randomly assigned to one of three groups two groups will receive different doses of efimosfermin, and one group will receive a placebo. All treatments are given as subcutaneous injections once every four weeks. The study will last up to 100 weeks for safety and includes monitoring drug levels in the blood up to 21 weeks. The comparison of two doses of efimosfermin versus placebo allows researchers to assess tolerability and drug behavior. During the trial, participants will be regularly assessed for any treatment-related side effects and have blood samples taken to measure drug concentrations. Researchers will monitor adverse events from the first day through 100 weeks. The study includes multiple visits for injections and evaluations. Participants will be observed closely to gather information on safety and the drugs effects over time, with the total duration extending up to nearly two years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Healthy Volunteer
Researchers are studying how a medicine called BI 1291583 is absorbed into the blood of adults aged 18 to 80 years, including those with and without liver problems. The study focuses on people with bronchiectasis, a chronic lung disease often accompanied by liver issues. Understanding how liver problems affect the medicines blood levels can help guide future treatments. Participants receive a single oral dose of BI 1291583. They are divided into four groups based on liver function healthy, mild, moderate, or severe liver impairment. Each healthy participant is matched with participants in the other groups by age, sex, smoking habits, and body weight to ensure fair comparisons. Liver impairment is classified using the Child-Pugh score, which assesses liver disease severity. The study lasts about three months with participants staying three days at the study site and attending up to nine visits. During these visits, doctors collect health information and take regular blood samples to measure the medicines levels over time. They also monitor participants for any side effects to evaluate safety and tolerability.
Actively Recruiting
Researchers are studying inebilizumab in people with autoimmune hepatitis AIH to evaluate its safety and how well it is tolerated Part 1, as well as its effect on AIH disease activity and the use of glucocorticoids in managing AIH Part 2. This research includes a phase 2 dose confirmation and safety part followed by a phase 3 efficacy evaluation without pausing enrollment. Participants receive either inebilizumab or a placebo as an intravenous infusion alongside their standard of care treatment. The study has multiple periods a screening period lasting up to 56 days a randomized controlled treatment period lasting 78 weeks divided into two parts an optional open-label period lasting up to 78 weeks for eligible participants after treatment and a safety follow-up period lasting up to 78 weeks. During the study, participants undergo various assessments including biopsies, blood tests measuring liver enzymes and immunoglobulin levels, and monitoring of glucocorticoid doses. Researchers measure safety outcomes such as treatment-emergent adverse events and efficacy outcomes like liver inflammation scores and stable prednisone doses. Participants are followed closely throughout all study phases, with total involvement potentially spanning several years.
Actively Recruiting
This trial evaluates the efficacy, safety, and tolerability of switching from glucagon-like peptide-1 receptor agonists GLP-1RA to maridebart cafraglutide in adults with obesity or overweight. It aims to assess how maridebart cafraglutide affects body weight and other safety measures in this population. The study is a Phase 3, open-label, randomized trial sponsored by Amgen. Participants are randomly assigned to one of two dosing schedules of maridebart cafraglutide, which is administered via subcutaneous injection. The treatment period involves receiving one of these dosing regimens to compare their effects. The study focuses on switching from prior weekly GLP-1RA treatment to maridebart cafraglutide and monitors participants throughout the treatment. During the trial, participants will have their body weight measured at baseline and at Week 68 to determine the percentage change. Additional assessments include plasma concentration of maridebart cafraglutide and monitoring for treatment-emergent adverse events up to 84 weeks. Participants are expected to maintain stable body weight and gastrointestinal tolerability before and during the trial, with contraception required for females. Overall, the study duration extends through the treatment period and safety follow-up.
1-10 of 15
1